- Previous Close
52.80 - Open
52.44 - Bid 52.45 x 100
- Ask 52.64 x 800
- Day's Range
51.68 - 52.78 - 52 Week Range
25.98 - 110.25 - Volume
932,097 - Avg. Volume
1,252,671 - Market Cap (intraday)
6.189B - Beta (5Y Monthly) 0.78
- PE Ratio (TTM)
-- - EPS (TTM)
-5.36 - Earnings Date Oct 31, 2024 - Nov 4, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
80.65
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
www.cytokinetics.comRecent News: CYTK
View More
Performance Overview: CYTK
Trailing total returns as of 10/1/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CYTK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CYTK
View MoreValuation Measures
Market Cap
6.19B
Enterprise Value
5.93B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.71k
Price/Book (mrq)
57.05
Enterprise Value/Revenue
1.89k
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-27.46%
Return on Equity (ttm)
--
Revenue (ttm)
3.13M
Net Income Avi to Common (ttm)
-545.28M
Diluted EPS (ttm)
-5.36
Balance Sheet and Cash Flow
Total Cash (mrq)
1.06B
Total Debt/Equity (mrq)
727.94%
Levered Free Cash Flow (ttm)
-233.93M
Research Analysis: CYTK
View MoreCompany Insights: CYTK
CYTK does not have Company Insights
Research Reports: CYTK
View MoreRaising target price to $45.00
CYTOKINETICS INC has an Investment Rating of SELL; a target price of $45.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetLowering target price to $43.00
CYTOKINETICS INC has an Investment Rating of SELL; a target price of $43.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetWhat does Argus have to say about CYTK?
CYTOKINETICS INC has an Investment Rating of SELL; a target price of $45.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of Medium.
RatingPrice TargetWhat does Argus have to say about CYTK?
CYTOKINETICS INC has an Investment Rating of SELL; a target price of $45.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of Medium.
RatingPrice Target